Men with Prostate Cancer Benefits 5-Alpha-Reductase Inhibitors, Study Shows

A recent study has unveiled that men with prostate cancer on active surveillance seem to fare well with 5-alpha-reductase inhibitors (5ARIs), which can help reduce both grade and volume progression without increasing risk of developing high-grade tumors.

Photo: Prostate Cancer Awareness | InStyleHealth


Research involved a group of 288 men with low-risk prostate cancer (PCa) from a prospectively maintained active surveillance database (1995 – 2016). With the total population, 85 were used 5ARI while 203 did not. Pathologic, grade, and volume progression were the primary endpoints.

Utilizing the Kaplan – Meier and Cox proportional hazards regression facilitated identification of progression in relation to 5ARI exposure as a time-dependent variable. Patients who came off active surveillance prior to any progression events were excluded.

With an average follow-up of 82 months, there were much fewer 5ARI users who had pathologic progression: there were only 24 as opposed to 114 non-users. The group of 5ARI users also experienced less frequent incidences of increased tumor volume and volume progression.

The non-use of 5ARI was verified to be positively correlated with pathologic progression, grade progression, and volume progression.

In the meantime, the frequency of progression to high-grade diseases was similar in users and non-users of 5ARI. For complete details of the clinical study, you may click here.

 

Source: Prostate Cancer Prostatic Dis 2021;24:69-76

If you have any suggestions, please let us know.

Post a Comment (0)
Previous Post Next Post